Our mission is to develop novel therapies to target against atherosclerosis (arterial blockages) and its consequences – heart attack and stroke.
Our treatment mission is to bypass arterial blockages by stimulating new blood vessel growth, to restore blood flow to affected regions.
Our central purpose is to develop therapies to treat atherosclerosis and promote cardiovascular regeneration. Such work will be performed in collaboration with the Clinical, Translational, Inflammation and Immunobiology Groups within the HRI, drawing upon their expertise in these areas of research.
What impact will this research have?
By reducing atherosclerotic plaque build up, we aim to reduce death and disability associated with heart and lower limb arterial disease. Also, by stimulating the growth of new blood vessels in patients with arterial blockages, our work aims to reduce symptoms associated with insufficient blood supply to the heart and legs.